Yesterday, futures tied to the Dow Jones Industrial Average fell by 111 points, or approximately 0.34%. S&P 500 futures declined by 0.28%, while Nasdaq 100 futures dropped by 0.25%. Our robots performed better than the market yesterday, as there was a slight increase in the broad market. However, it is still not sufficient to speak of a strong growing market. The broad market remains weak, and only individual stocks are showing some upward movement.
Our robots have been able to make profits from short positions on certain stocks. One example is Pfizer, which our robots were short on, and it lost over 1.5% yesterday. The market is very volatile, and I recommend exercising caution when making trades at the moment. However, it is likely that the market will determine its direction in the near future.
The Stochastic Oscillator appears to be transitioning from an upward trend to a downward trend. In 34 out of 59 instances where PFE's Stochastic Oscillator exited the overbought zone, the price subsequently declined within the following month. The likelihood of a continued downward trend is estimated at 58%.
The Momentum Indicator dropped below the 0 level on May 30, 2023. In 47 out of 83 cases where the Momentum Indicator fell below 0, the stock continued to decline within the subsequent month. The odds of a continued downward trend are calculated at 57%.
Following a 3-day decline, it is expected that the stock will experience further falls. Historical data shows that in 50 out of 62 cases where PFE declined for three consecutive days, the price subsequently rose within the following month. The probability of a continued downward trend is estimated at 60%.
PFE broke above its upper Bollinger Band on May 23, 2023. This breakout may indicate an impending drop in the stock's price as it moves back below the upper band towards the middle band. It might be worth considering selling the stock or exploring put options.
The Aroon Indicator for PFE shifted into a downward trend on May 23, 2023. This suggests a potential strong downward movement for the stock. Traders may want to consider selling the stock or purchasing put options.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
PFE's Aroon Indicator triggered a bullish signal on September 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 192 similar instances where the Aroon Indicator showed a similar pattern. In 115 of the 192 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 60%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 149 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The 10-day RSI Indicator for PFE moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 15 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 25 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.922) is normal, around the industry mean (19.199). P/E Ratio (37.789) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). PFE has a moderately high Dividend Yield (0.060) as compared to the industry average of (0.025). P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor